China's AI-Driven Drug Discovery Sector: 113 Companies as of January 2026 Signal Industry Maturation and Commercial Breakthroughs

Jan 05, 2026 18:08 CST Updated 18:09

Byterna is a biopharmaceutical

CAR-T Cell Therapy Researcher

As of2026Year 1Month,According to incomplete statistics from IntelPharm,ChinaAIThe pharmaceutical company has reached113Home。

Among them, 94% of the companies are densely distributed in Beijing, the Yangtze River Delta, and the Greater Bay Area, with significant agglomeration effects in Beijing, Shanghai, and Shenzhen, forming a "tripod" situation.

In the past 2025, AI pharmaceuticals in ChinaClinical Proof of ConceptAndCommercial Value RealizationAchieved dual breakthroughs.

In summary, the industry is transitioning from the early stage of technological exploration to a phase of deep industrial cultivation marked by specific drug pipelines and massive collaborations.

The following is a map of AI + drug research and development companies in China (red indicates newly added companies):

The 2 newly added companies include:

Noah AI:Founded inIn 2023,Composed of teams from top global pharmaceutical companies, AI, and Internet technology firms. Noah AI is committed toBuildArtificial Intelligence Agent (AI Agent), helping the pharmaceutical R&D and manufacturing fields solve complex tasks.

Byterna Therapeutics:Founded in June 2023, it is a biopharmaceutical innovation enterprise driven by AI, circular mRNA, and targeted tLNP technology.The company was founded by former Fudan University School of Pharmacy Associate Professor Xian Zeng and Dr. Hui Zhao.Founded by Byterna Therapeutics. Currently, Byterna Therapeutics has achieved technological breakthroughs in high-barrier areas such as seamless and efficient cyclization, AI sequence design, circular mRNA chemical modification, in vivo T-cell targeted delivery, and circular mRNA CAR design and evaluation. The company has established multiple in vivo CAR-T pipelines, with its core pipeline rapidly advancing into clinical research.

Various regions continue to intensify efforts, with Beijing, Shanghai, and Shenzhen leading the way.

According to the statistics from Intellicure, ChinaAIPharmaceutical companies are mainly distributed in three regions: Beijing, the Yangtze River Delta, and the Greater Bay Area, encompassing over94%TheAIPharmaceutical company.

Among which,Beijing, ShanghaiAndShenzhenThree cities stand out, each with approximately20Home CompanyLanding。

On the one hand, it is because artificial intelligence, as a cutting-edge technology, exceeds30The technology of these companies stems from the transformation of achievements in universities or research institutes, so it is necessary to cooperate closely with universities and research institutions. Peking University, Tsinghua University, Shanghai Jiao Tong University, and the Chinese Academy of Sciences all have profound accumulations.

For example, multiple colleges and industrial research institutes of Tsinghua University have made efforts, incubating companies including Shuimu Future, HuaShen ZhiYao, and Shuimu Molecular.

On the other hand, the industrial chains in Beijing, the Yangtze River Delta, and the Greater Bay Area are well-developed, with some positioned atCROTheAIPharmaceutical companies also find it easier to acquire customers. Besides, the advanced industry and policy support are also inseparable.

Zhangjiang, with a keen sense of smell, walks at the forefront.2021In ... , Zhangjiang took the lead in establishing"ZhangjiangAINew Drug R&D Alliance, which has been established for more than3Year, every year there is more than10Companies Join the Alliance, IncludingAIPharmaceutical companies,CRO, multinational pharmaceutical companies, etc., expand Zhangjiang inAIThe Influence of Pharmaceutical Manufacturing.

The Several Opinions on Supporting the Full-Chain Innovative Development of the Biomedical Industry issued by the Shanghai Municipal Government clearly states:Support AI technology in empowering drug research and development.

In addition, the Shenzhen Municipal Government released"Several Measures of Shenzhen City to Fully Support the Development of Pharmaceuticals and Medical Devices"It also pointed out that support will be given to the construction of a number of major public service platforms and major industrial projects for AI drug and device R&D, including high-throughput drug screening, next-generation antibody drug discovery, and AI medical device development.

Professors are the main force in entrepreneurship

According to the founder/Different Backgrounds of the Team, ChinaAIThe company is mainly divided into6Class:University/Institute's technology transfer, Internet giants, returned overseas Ph.D., senior pharmaceutical industry expert, Internet entrepreneur.

Among them, the founder has a university/The background of the research institute almost occupies half of the landscape, with as many as48companies, not including those with university professors as co-founders or chief scientists.

Among the companies incubated in universities/research institutes, those transformed from CAS, Peking University, Tsinghua University, and Shanghai Jiao Tong University are particularly the most numerous.

In addition, due to the characteristics of artificial intelligence products,AIThe pharmaceutical industry has also welcomed a group of cross-disciplinary practitioners, including returned overseas PhDs and individuals from the internet sector.

In terms of establishment time, China respectively in2018Year and2021A wave of entrepreneurship emerged in different years, respectively.14Harmony at Home31Establishment of the company.

Companies that have received financing in ChinaAIIn pharmaceutical companies,Apart from Drug Farm, Deep Potential Technology, and Metason Therapeutics, which have already advanced toCOutside of the round, the vast majority are at the angel round.A+Round stage, only1Company ObtainsB+Few companies reach the middle and later rounds of financing.

2025. Rapid Progress in Business and Clinical Fields

2025 is a pivotal year for China's AI-driven pharmaceuticals sector, transitioning from technical validation to value realization.

Industry inCore Technology Original Innovation, Pipeline Clinical Progress, Major Commercial Collaborations, and Industrial Ecosystem Developmentand other aspects have achieved a series of landmark breakthroughs.

In terms of business model,Insilico Medicine successfully listed on the Hong Kong Stock Exchange on December 30, 2025.Hong Kong Public Offering Obtained1427xOversubscribed, setting a record for the year. This indicatesMainstream Capital in the Secondary MarketWith unprecedented enthusiasm, the prospect of AI pharmaceuticals has been recognized, for the company"Software Subscription+ Pipeline Authorization+ Recognition of the "Joint Development" business model.

InInnovative Drug ExportAspect,Large-scale collaborations between leading AI pharmaceutical companies and multinational pharmaceutical corporations are a core indicator of industry value realization.

April 17,HelixonOverseas SubsidiariesEarendil LabsAnd Sanofi reached an external agreement. Sanofi will obtain twoBispecific Antibodies HXN-1002 and HXN-1003The global exclusive rights for the treatment of autoimmune and inflammatory bowel disease fields.

In the transaction, Earendil Labs will acquire$125 millionThe advance payment,And is eligible to receive up to$1.72 billionDevelopment and commercialization milestone payments,And tiered royalty fees for product sales.

June 13,CSPC GroupAndAstraZenecaStrategic Research Collaboration Reached, Leveraging CSPC Group's AIDrivenDual Drug Discovery Platform.According to the agreement, CSPC will obtain$110 millionThe upfront payment, with eligibility for up to $1.62 billion in potential development milestone payments and up to $3.6 billion in sales milestone payments.

In addition,XtalPiCapture the total scale of nearlyHK$47 billionThe "AI + Robotics" drug R&D order sets an industry record.

In terms of drug advancements，NeoCuramRNA PersonalizedTumor Neoantigen Vaccine XH001Approved to initiate clinical research;DearDrugAnnouncement of Its AI-Designed Small MoleculesGLP-1 Receptor Agonist MDR-001Entering Phase III clinical trials, becomingChina's First AI Innovation Drug to Enter Phase III Clinical Trials；Yudao BioDrug Product for Advanced Solid Tumors in DevelopmentNTS071Obtained clinical approval.

In conclusion

In 2026, China's AI pharmaceuticals industry will welcomeCommercial Value ValidationAndDeep Integration of TechnologyThe acceleration period.

China's AI pharmaceuticals industry is embracing significant opportunities while also facing challenges such as consensus building and the accumulation of high-quality data.。

In the short term,The Approval of the First AI-Developed DrugWill become a milestone that ignites the industry. In the long term, the industry's success will depend on whether it can continuously produce drugs with clinical value and build a system based onA New Era of Drug Development Based on Independent Innovation Technology Platforms.

China, with its comprehensive advantages in technology, supply chain, and market, is expected to play a leading role in this paradigm revolution of global pharmaceutical R&D.

—The End—

Recommended Reading